We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel Therapies for Aggressive B-Cell Lymphoma.
- Authors
Foon, Kenneth A.; Takeshita, Kenichi; Zinzani, Pier L.
- Abstract
Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.
- Subjects
B cell lymphoma; RITUXIMAB; BURKITT'S lymphoma; CANCER invasiveness; RESPONSE rates; BLOOD diseases; CANCER chemotherapy; IMMUNOTHERAPY; TUMOR treatment
- Publication
Advances in Hematology, 2012, p1
- ISSN
1687-9104
- Publication type
Article
- DOI
10.1155/2012/302570